Dendritic Cell-Dead Cell Interactions: Implications and Relevance for Immunotherapy

Journal of Immunotherapy

Volumn 24, Issue 4, 2001, Pages 294-304

  Fonteneau, Jean Francois ^a   Larsson, Marie ^a   Bhardwaj, Nina ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Cell death; Dendritic cell; Immunotherapy; T lymphocyte; Viral and tumoral immunity

Indexed keywords

HLA ANTIGEN CLASS 1;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; APOPTOSIS; CELL INTERACTION; CELL STIMULATION; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY;

ANTIGEN-PRESENTING CELLS; APOPTOSIS; CELL COMMUNICATION; CELL DEATH; DENDRITIC CELLS; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0034851147     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200107000-00005     Document Type: Review

References (95)

1. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996; 272: 60-7.
2. Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 1976; 143: 1283-8.
3. Bevan MJ. in a radiation chimera host H-2 antigens determine the immune responsiveness of donor cytotoxic cells. Nature 1977; 269: 417-8.
4. Heath WR, Kurts C, Miller JFAP, Carbone FR. Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens. J Exp Med 1998; 187: 1549-53.
5. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001; 19: 47-64.
6. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52.
7. Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000; 191: 411-6.
8. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate antigen in the major histocompatibility class II compartment. Downregulation by cytokines and bacterial products. J Exp Med 1995; 182: 389-400.
9. Regnault A, Lankar D, Lacabanne V, et al. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999; 189: 371-80.
10. Mahnke K, Guo M, Lee S, et al. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via MHCII+, lysosomal compartments. J Cell Biol 2000; 151: 673-83.
11. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392: 86-9.
12. Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. Tumor-specific and anti-neuronal killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998; 4: 1321-4.
13. Zitvogel L, Regnault A, Lozier A, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998; 4: 594-600.
14. Yrlid U, Wick MJ. Salmonella-induced apoptosis of infected macrophages results in presentation of a bacteria-encoded antigen after uptake by bystander dendritic cells. J Exp Med 2000; 191: 613-23.
15. Sallusto F, Schaerli P, Loetscher P, et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 1998; 28: 2760-9.
16. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T helper and a T-killer cell. Nature 1998; 393: 474-8.
17. Bennett SRM, Carbone FR, Karamalis F, Flavell RA, Miller JFAP, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393: 478-80.
18. Schoenberger SP, Toes REM, van der Voort EIH, Offringa R, Melief CJM. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393: 480-3.
19. Lu Z, Yuan L, Zhou X, Sotomayor E, Levitsky HI, Pardoll DM. CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. J Exp Med 2000; 191: 541-50.
20. Kurts C, Heath WR, Carbone FR, Allison J, Miller JFAP, Kosaka H. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J Exp Med 1996; 184: 923-30.
21. Gooding LR, Edwards CB. H-2 antigen requirements in the in vitro induction of SV40-specific cytotoxic T lymphocytes. J Immunol 1980; 124: 1258-62.
22. Sigal LJ, Crotty S, Andino R, Rock KL. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 1999; 398: 77-80.
23. Pfeifer JD, Wick MJ, Roberts RL, Findlay K, Normark SJ, Harding CV. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 1993; 361: 359-62.
24. Jenne L, Arrighi J, Sauter B, Kern P. Dendritic cells pulsed with unfractionated helminthic proteins to generate antiparasitic cytotoxic T lymphocyte. Parasite Immunol 2001; 23: 195-202.
25. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll DM, Levitsky HI. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994; 264: 961-5.
26. Yewdell JW, Norbury CC, Bennink JR. Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. Adv Immunol 1999; 73: 1-77.
27. Herr W, Ranieri E, Olson W, Zarour H, Gesualdo L, Storkus WJ. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood 2000; 96: 1857-64.
28. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunology 1998; 8: 657-65.
29. Harshyne L, Watkins S, Gambotto A, Barratt-Boyes S. Dendritic cells acquire antigens from live cells for cross-presentation to CTL. J Immunol 2001; 166: 3717-23.
30. Lenz LL, Butz EA, Bevan MJ. Requirements for bone marrow-derived antigen-presenting cells in priming cytotoxic T cell responses to intracellular pathogens. J Exp Med 2000; 192: 1135-42.
31. Ke Y, Kapp JA. Exogenous antigens gain access to the major histocompatibility complex class I processing pathway in B cells by receptor-mediator uptake. J Exp Med 1996; 184: 1179-84.
32. Norbury CC, Hewlett LJ, Prescott AR, Shastri N, Watts C. Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Immunology 1995; 3: 783-91.
33. Sigal LJ, Rock KL. Bone marrow-derived antigen-presenting cells are required for the generation of cytotoxic T lymphocyte responses to viruses and use transporter associated with antigen presentation (TAP)-dependent and-independent pathways of antigen presentation. J Exp Med 2000; 192: 1143-50.
34. Kovacsovics-Bankowski M, Rock KL. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 1995; 267: 243-6.
35. Bellone M, Iezzi G, Rovere P, et al. Processing of engulfed apoptotic bodies yields T cell epitopes. J Immunol 1997; 159: 5391-9.
36. Larsson M, Messmer D, Somersan S, et al. Requirement of mature dendritic cells for efficient activation of influenza-specific memory CD8+ T cells. J Immunol 2000; 165: 1182-90.
37. Ronchetti A, Rovere P, Iezzi G, et al. Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J Immunol 1999; 163: 130-6.
38. Pulaski BA, Yeh KY, Shastri N, et al. Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex “re-presentation” of exogenous antigen by tumor-infiltrating antigen-presenting cells. Proc Natl Acad Sci USA 1996; 93: 3669-74.
39. den Haan J, Lehar S, Bevan M. CD8+ but not CD8− dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 2000; 192: 1685-96.
40. Pooley JL, Heath WR, Shortman K. Intravenous soluble antigen is presented to CD4 T cells by CD8(−) dendritic cells, but cross-presented to CD8 T cells by CD8(+) dendritic cells. J Immunol 2001; 166: 5327-30.
41. Kurts C, Cannarile M, Klebba I, Brocker T. Dendritic cells are sufficient to cross-present self-antigens to CD8 T cells in vivo. J Immunol 2001; 166: 1439-42.
42. Huang AYC, Bruce AT, Pardoll DM, Levitsky HI. in vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunology 1996; 4: 349-55.
43. Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1999; 1: 362-8.
44. Harding CV, Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J Immunol 1994; 153: 4925-33.
45. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-6.
46. Restifo N. Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. Curr Opin Immunol 2000; 12: 597-603.
47. Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature 2000; 407: 784-8.
48. Boisteau O, Gautier F, Cordel S, et al. Apoptosis induced by sodium butyrate treatment increases immunogenicity of a rat colon tumor cell line. Apoptosis 1997; 2: 403-12.
49. Inaba K, Turley S, Yamaide F, et al. Efficient presentation of phagocytosed cellular fragments on the MHC class II products of dendritic cells. J Exp Med 1998; 188: 2163-73.
50. Russo V, Tanzarella S, Dalerba P, et al. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. Proc Natl Acad Sci USA 2000; 97: 2185-90.
51. Hoffmann TK, Meidenbauer N, Dworacki G, Kanaya H, Whiteside TL. Generation of tumor-specific T lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 2000; 60: 3542-9.
52. Jenne L, Arright J, Jonuleit H, Saurat J, Hauser C. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. Cancer Res 2000; 60: 4446-52.
53. Arrode G, Boccaccio C, Lule J, et al. Incoming human cytomegalovirus pp65 (UL83) contained in apoptotic infected fibroblasts is cross-presented to CD8(+) T cells by dendritic cells. J Virol 2000; 74: 10018-24.
54. Berard F, Blanco P, Davoust J, et al. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 2000; 192: 1535-44.